ERBB2 and non-small cell lung carcinoma: In the near future, the first-line therapy for patients with ERBB2-mutated NSCLC may change based on the results of phase III studies on T-DXd, zongertinib, and BAY2927088 compared to standard chemotherapy plus ICI therapy.